Elicit: Clinical Outcomes of Aflibercept in AMD and DME

Clinical Outcomes of Aflibercept in AMD and DME

What clinical outcomes support aflibercept treatment of wet AMD and diabetic macular edema?

Aflibercept treatment for wet AMD and diabetic macular edema is supported by visual acuity improvements equivalent to ranibizumab and superior to laser photocoagulation, significant anatomical improvements including central retinal thickness reductions and diabetic retinopathy severity improvements, clinically meaningful quality of life gains, and a safety profile comparable to other anti-VEGF agents with the advantage of less frequent dosing.

Abstract

Aflibercept treatment for wet age-related macular degeneration produces visual acuity outcomes equivalent to ranibizumab, with both treatments showing similar mean BCVA changes (within 0.5 letters) and approximately 32% of patients gaining ≥15 letters at one year. Anatomical outcomes were also similar, with comparable proportions achieving dry retina (RR 1.06, 95% CI 0.98 to 1.14) and equivalent choroidal neovascularization area reductions. For diabetic macular edema, aflibercept demonstrated statistically significant superiority over laser photocoagulation, with mean BCVA gains of 10.5-13.6 letters compared to -0.5 to 1.2 letters for laser (p<0.0001), and central retinal thickness reductions of 183-195 μm versus 66-73 μm for laser (p<0.0001). At 148 weeks, 35.8-42.9% of aflibercept-treated eyes gained ≥15 letters versus 13.6-18.9% with laser. Aflibercept showed non-inferiority to bevacizumab (mean improvement 15.0 versus 14.0 letters, p=0.37) and better anatomical outcomes than ranibizumab in real-world practice (central subfield thickness reduction -114.4 μm versus -87.8 μm, p<0.01). Quality of life improved meaningfully in both conditions, with NEI VFQ-25 total score gains of +6.11 points in DME and clinically significant improvements across multiple subscales in wet AMD. The safety profile was comparable to other anti-VEGF agents, with serious systemic adverse events similar to ranibizumab (RR 0.99, 95% CI 0.79 to 1.25) and no new safety signals identified in long-term use. The every-8-weeks maintenance dosing regimen after initial loading reduced treatment burden compared to monthly regimens while maintaining efficacy.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

n = 200

Papers screened using:

Target Population, Intervention, Clinical Outcomes, Study Design, Follow-up Duration, Aflibercept Analysis, Study Quality and Accessibility, Study Scope
n = 200 Papers screened out
n = 190 Papers included for extraction
n = 10

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

Screening

We screened in sources based on their abstracts that met these criteria:

Target Population: Patients diagnosed with wet AMD (neovascular age-related macular degeneration) or diabetic macular edema.
Intervention: Study examining aflibercept (Eylea) administered as intravitreal injection.
Clinical Outcomes: Reporting clinical outcomes related to visual function, anatomical changes, or safety.
Study Design: Randomized controlled trial, controlled clinical trial, large prospective cohort study (n≥50), or systematic review/meta-analysis.
Follow-up Duration: Minimum 12-week follow-up period.
Aflibercept Analysis: Aflibercept outcomes can be separately analyzed.
Study Quality and Accessibility: Not a case report, case series with <10 patients, editorial/commentary, or conference abstract without full-text publication.
Study Scope: Focused on ophthalmic indications and specifically on wet AMD or diabetic macular edema.

Data extraction

We asked a large language model to extract data on the following:

Study Design

Study type (RCT, observational, etc.)
Sample size and number of eyes treated with aflibercept
Patient population (wet AMD or diabetic macular edema or both)
Baseline disease characteristics
Comparator group(s) if any
Follow-up duration

Visual Outcomes

Best-corrected visual acuity (BCVA) changes from baseline
Proportion gaining ≥15 letters
Proportion losing ≥15 letters
Statistical significance and confidence intervals
Time points assessed

Anatomical Outcomes

Central retinal thickness changes
Proportion achieving dry retina
Choroidal neovascularization area changes
Statistical significance and effect sizes

Quality of Life

Vision-related quality of life scales (NEI VFQ-25 scores)
Changes from baseline and clinical significance

Safety Profile

Serious ocular adverse events
Treatment-emergent adverse events by category
Rates and risk ratios compared to control groups

Treatment Regimen

Dose administered
Initial loading schedule
Maintenance schedule
Total number of injections over study period

Comparative Effectiveness

Direct comparisons to ranibizumab, bevacizumab, or laser photocoagulation
Non-inferiority or superiority findings

Key Limitations

Risk of bias concerns
Generalizability limitations

Results

Characteristics of included studies

The systematic review included 10 sources examining aflibercept treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

Study	Full text retrieved?	Study Type	Sample Size	Patient Population	Comparator	Follow-up Duration
J. Heier et al., 2012	Yes	RCT	2419 patients	Wet AMD	Ranibizumab	52 weeks
J. M. Ruiz-Moreno, 2015	No	Phase III RCT	461/402 patients	DME	Laser	52 weeks
J. Heier et al., 2016	No	Phase III RCT	872 eyes	DME	Laser	148 weeks
Chirag Jhaveri et al., 2022	No	RCT	312 eyes (158 aflibercept)	DME	Bevacizumab first	2 years
You-Xin Chen et al., 2020	No	Phase III RCT	127 eyes per group	DME	Laser	52 weeks
Pierre-Henry Gabrielle et al., 2022	No	Retrospective	534 eyes (267 aflibercept)	DME	Ranibizumab	3 years
S. Sarwar et al., 2016	No	Cochrane review	2457 participants	Wet AMD	Ranibizumab	1-2 years
J. Carrasco et al., 2021	Yes	Meta-analysis	40-2506 patients/eyes	Wet AMD	None	2 years
M. Yuzawa et al., 2015	No	Phase III RCT	2419 patients (607 aflibercept)	Wet AMD	Ranibizumab	52 weeks
J. Garweg et al., 2019	No	Phase IV single-arm	553 patients	DME	None	52 weeks

Effects

Visual Acuity Outcomes in Wet AMD

Aflibercept demonstrated substantial and sustained visual acuity improvements in wet AMD across multiple studies. In the VIEW trials comparing aflibercept to ranibizumab, all aflibercept regimens were within 0.5 letters of ranibizumab for mean change in BCVA, demonstrating clinical equivalence.

Study	Time Point	Mean BCVA Change	Proportion Gaining ≥15 Letters	Statistical Significance
S. Sarwar et al., 2016	1 year	-0.15 letters	~32%	High-quality evidence
S. Sarwar et al., 2016	2 years	7.2 letters	~31%	High-quality evidence
J. Carrasco et al., 2021	2 years	+4.49 letters	47.39%	Not specified
M. Yuzawa et al., 2015	52 weeks	Similar improvements in NEI VFQ-25	Not reported	Similar to ranibizumab

Visual Acuity Outcomes in Diabetic Macular Edema

Aflibercept demonstrated consistent superiority over laser photocoagulation and non-inferiority to other anti-VEGF agents in DME.

Study	Time Point	Aflibercept Regimen	Mean BCVA Gain	Comparator BCVA Gain	p-value
J. M. Ruiz-Moreno, 2015	52 weeks	2q4 (VISTA)	12.5 letters	0.2 letters (laser)	p<0.0001
J. M. Ruiz-Moreno, 2015	52 weeks	2q8 (VISTA)	10.5 letters	1.2 letters (laser)	p<0.0001
J. Heier et al., 2016	148 weeks	2q4 (VISTA)	10.4 letters	1.4 letters (laser)	p<0.0001
You-Xin Chen et al., 2020	52 weeks	2q4	+13.6 letters	-0.5 letters (laser)	p<0.0001

Anatomical Outcomes

Aflibercept produced significant anatomical improvements in both wet AMD and DME.

Study	Time Point	Aflibercept CRT Change (2q4)	Aflibercept CRT Change (2q8)	Comparator CRT Change	p-value
J. M. Ruiz-Moreno, 2015	52 weeks (VISTA)	-185.9 μm	-183.1 μm	-73.3 μm (laser)	p<0.0001
J. M. Ruiz-Moreno, 2015	52 weeks (VIVID)	-195.0 μm	-192.4 μm	-66.2 μm (laser)	p<0.0001
J. Garweg et al., 2019	52 weeks	-175.38 μm (SD 132.62)	N/A	N/A	N/A
Pierre-Henry Gabrielle et al., 2022	3 years	N/A	-114.4 μm	-87.8 μm (ranibizumab)	p<0.01

Vision-Related Quality of Life

Quality of life assessments demonstrated clinically meaningful improvements with aflibercept treatment.

Quality of Life Measure	Week 52 Change	Clinical Significance
NEI VFQ-25 total score	+6.11	Clinically meaningful
Near activities subscale	+11.37	More pronounced than distance
Distance activities subscale	+7.33	Clinically meaningful
Better-seeing eye	+7.74	Comprehensive improvement
Worse-seeing eye	+5.48	Clinically meaningful

Safety Profile

The safety profile of aflibercept was generally favorable and comparable to other anti-VEGF agents.

Study	Serious Ocular Adverse Events	Treatment-Emergent Adverse Events	Safety Conclusion
J. M. Ruiz-Moreno, 2015	Similar across groups	Similar ocular and nonocular events	Comparable to laser
J. Heier et al., 2016	Cataract rates specified	Consistent with known profile	Known safety profile maintained
Chirag Jhaveri et al., 2022	Not specified	More events with aflibercept	Increasing caution needed
You-Xin Chen et al., 2020	Not specified	Low rates across groups	Consistent safety profile

Treatment Regimens

Aflibercept was administered at a dose of 2 mg across all studies. Two primary dosing regimens emerged:

Every 4 weeks regimen (2q4): Monthly injections throughout the treatment period.
Every 8 weeks regimen (2q8): Initial loading doses followed by maintenance dosing every 8 weeks.

The eight-week dosing regimen facilitated reduced treatment burden compared to monthly regimens while maintaining efficacy.

Comparative Effectiveness

Aflibercept demonstrated non-inferiority to ranibizumab in wet AMD and superiority to laser photocoagulation in DME.

Key Limitations

There were risk of bias concerns primarily due to the observational nature of some studies leading to questions about generalizability and potential confounding factors.